Clinical, Cosmetic and Investigational Dermatology (Dec 2022)

Evaluation of the Efficacy and Safety of Apremilast in the Management of Lichen Planus

  • Viswanath V,
  • Joshi P,
  • Dhakne M,
  • Dhoot D,
  • Mahadkar N,
  • Barkate H

Journal volume & issue
Vol. Volume 15
pp. 2593 – 2600

Abstract

Read online

Vishalakshi Viswanath,1 Pradnya Joshi,1 Mayuri Dhakne,1 Dhiraj Dhoot,2 Namrata Mahadkar,2 Hanmant Barkate2 1Department of Dermatology, Rajiv Gandhi Medical College, Thane, Maharashtra, India; 2Global Medical Affairs, Glenmark Pharmaceuticals Ltd, Mumbai, Maharashtra, IndiaCorrespondence: Namrata Mahadkar, Email [email protected]: Lichen planus is a chronic disease with often disappointing and less than optimal treatment options. Apremilast modulates inflammatory signalling pathways which play a central role in the pathogenesis of lichen planus, thus making it useful in the management of such patients.Materials and Methods: The present study was an investigator-initiated, single-centre, non-randomized, open-label, pilot study of the efficacy and safety of Apremilast in the treatment of lichen planus. All the patients were prescribed Apremilast 30mg, twice daily, for 12 weeks. Patients were evaluated for improvement in their lesions, based on the physician’s global assessment (PGA), subject global assessment (SGA), and target area lesion symptom score (TALSS).Results: A total of 34 patients were included in the study; 26 patients completed the study duration and were considered for the final analysis. After 12 weeks, 34.61% (n = 9/26) patients showed 2 or more grade improvement in their disease as per PGA. About 42.30% (n = 11/26) patients achieved more than 50% improvement in their lesions based on the subject global assessment of their disease. There was a significant improvement in TALSS during the study period (p < 0.0001). Only 23.07% (n = 6/26) patients developed one or more adverse events because of Apremilast with headache being the commonest side effect.Conclusion: The results obtained in our study justify that Apremilast is efficacious and safe in the management of patients with lichen planus. Based on these results, Apremilast can be considered as a promising alternative treatment option in patients with lichen planus.Keywords: Apremilast, lichen planus, efficacy, safety

Keywords